Growth Metrics

Myriad Genetics (MYGN) Non-Current Deferred Tax Liability (2016 - 2023)

Historic Non-Current Deferred Tax Liability for Myriad Genetics (MYGN) over the last 10 years, with Q3 2023 value amounting to $2.7 million.

  • Myriad Genetics' Non-Current Deferred Tax Liability fell 7428.57% to $2.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.7 million, marking a year-over-year decrease of 7428.57%. This contributed to the annual value of $3.5 million for FY2022, which is 9727.84% down from last year.
  • Per Myriad Genetics' latest filing, its Non-Current Deferred Tax Liability stood at $2.7 million for Q3 2023, which was down 7428.57% from $3.7 million recorded in Q2 2023.
  • Myriad Genetics' Non-Current Deferred Tax Liability's 5-year high stood at $174.3 million during Q4 2020, with a 5-year trough of $2.7 million in Q3 2023.
  • For the 5-year period, Myriad Genetics' Non-Current Deferred Tax Liability averaged around $52.7 million, with its median value being $58.2 million (2021).
  • In the last 5 years, Myriad Genetics' Non-Current Deferred Tax Liability soared by 13086.09% in 2020 and then plummeted by 9727.84% in 2022.
  • Quarter analysis of 5 years shows Myriad Genetics' Non-Current Deferred Tax Liability stood at $75.5 million in 2019, then soared by 130.86% to $174.3 million in 2020, then fell by 26.22% to $128.6 million in 2021, then crashed by 97.28% to $3.5 million in 2022, then dropped by 22.86% to $2.7 million in 2023.
  • Its last three reported values are $2.7 million in Q3 2023, $3.7 million for Q2 2023, and $4.1 million during Q1 2023.